Subsequent studies investigating tumor fucosylation, total/fucosylated HLA-DRB1 and CD4+ T cells as biomarkers will need to factor for clinical variables including therapies received before anti-PD1 therapy and pre-existing medical conditions as well as time from biopsy to anti-PD1 treatment. This evidence concerns the gene PDCD1 and neoplasm.